Company profile: Sparrow Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for disorders of corticosteroid excess, including SPI-62, an oral HSD-1 inhibitor designed to reduce intracellular cortisol in conditions like endogenous Cushing’s syndrome and autonomous cortisol secretion, and SPI-47, combining SPI-62 with prednisolone for autoimmune diseases such as polymyalgia rheumatica.
Products and services
- Corticosteroid Excess Treatment Development: Clinical-stage biopharmaceutical programs developing treatments for disorders of corticosteroid excess, exemplified by therapeutics addressing endogenous Cushing’s syndrome and autonomous cortisol secretion
- SPI-47: A combination therapy pairing the HSD-1 inhibitor SPI-62 with prednisolone to treat autoimmune diseases like polymyalgia rheumatica, reducing inflammation with fewer side effects
- SPI-62: An oral HSD-1 inhibitor that reduces intracellular cortisol to mitigate adverse effects in endogenous Cushing’s syndrome and autonomous cortisol secretion, targeting corticosteroid excess
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sparrow Pharmaceuticals
Step Pharma
HQ: France
Website
- Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Step Pharma company profile →
Aclaris Therapeutics
HQ: United States
Website
- Description: Provider of dermatologic and immuno-inflammatory therapies R&D, using its KINect platform to discover small-molecule kinase inhibitors; conducts clinical trials; offers drug discovery and early development via Confluence Discovery Technologies; advancing ATI-1777 (topical JAK1/JAK3), ATI-2138 (oral ITK/JAK3), and Zunsemetinib/ATI-450 (oral MK2) for metastatic breast cancer and pancreatic ductal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aclaris Therapeutics company profile →
NapaJen
HQ: United States
Website
- Description: Provider of oligonucleotide therapeutics and delivery technologies, offering NJA-730 for preventing acute immune diseases tied to bone marrow transplants; Napa9-SPG, a TLR9 agonist in preclinical immuno-oncology and vaccine adjuvant use; and a proprietary platform delivering nucleic acid drugs to immune cells. Provides partnerships for oligonucleotide development and NJA-730 licensing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NapaJen company profile →
IMMCO Diagnostics
HQ: United States
Website
- Description: Provider of innovative medical devices, diagnostic laboratory testing expertise, and pioneering research for a comprehensive solution to autoimmune disease diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IMMCO Diagnostics company profile →
Statera Biopharma
HQ: United States
Website
- Description: Provider of biotechnology research services and immune-restorative drug development, advancing STAT-201 for pediatric Crohn's, STAT-205 for acute and post-acute COVID-19, STAT-401 as an adjunct for pancreatic cancer, the AIMS platform targeting complex pathways and toll-like receptors, and Entolimod, a TLR5 agonist for radio-mitigation in cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Statera Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sparrow Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sparrow Pharmaceuticals
2.2 - Growth funds investing in similar companies to Sparrow Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sparrow Pharmaceuticals
4.2 - Public trading comparable groups for Sparrow Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →